Group 1 - Edward Lifesciences announced the launch of the MITRIS RESILIA valve in China, which utilizes RESILIA technology for enhanced durability and offers a sustainable solution for patients requiring mitral valve replacement [1] - The MITRIS RESILIA valve is the first surgical bioprosthetic mitral valve to adopt the RESILIA fully enclosed anti-calcification technology, providing a new management solution for patients in China [1][2] - The valve has also received regulatory approval in the United States, Japan, and Canada, indicating its global market acceptance [1] Group 2 - The prevalence of cardiovascular diseases, particularly heart valve diseases, is increasing in China due to an aging population, making it the third most common cardiovascular condition after coronary heart disease and hypertension [2] - Surgical replacement remains the most widely used treatment for mitral valve diseases, with a trend towards less invasive, more durable, and personalized approaches [2] - The demand for minimally invasive surgical techniques is rising, as they reduce surgical trauma and improve patient outcomes [2] Group 3 - The MITRIS RESILIA valve features innovative RESILIA tissue processing technology that enhances valve durability by sealing the sources of calcification [3] - The valve's soft suture ring and low-profile design facilitate easier implantation, making it suitable for minimally invasive surgeries [3] - The valve's large opening design allows for future "valve-in-valve" interventions, ensuring a comprehensive solution for patients throughout their treatment journey [3]